These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17402800)

  • 1. Panitumumab in the treatment of metastatic colorectal cancer: profile report.
    Hoy SM; Wagstaff AJ
    BioDrugs; 2007; 21(2):135-7. PubMed ID: 17402800
    [No Abstract]   [Full Text] [Related]  

  • 2. Integration of the anti-EGFR agent panitumumab into clinical practice in metastatic colorectal cancer.
    Van Cutsem E
    Clin Adv Hematol Oncol; 2007 Aug; 5(8):611-3. PubMed ID: 17982400
    [No Abstract]   [Full Text] [Related]  

  • 3. Panitumumab.
    Saltz L; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2006 Dec; 5(12):987-8. PubMed ID: 17201026
    [No Abstract]   [Full Text] [Related]  

  • 4. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panitumumab (Vectibix) for metastatic colorectal cancer.
    Med Lett Drugs Ther; 2007 Apr; 49(1259):35-6. PubMed ID: 17450113
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.
    Heun J; Holen K
    Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.
    Saadeh CE; Lee HS
    Ann Pharmacother; 2007 Apr; 41(4):606-13. PubMed ID: 17355997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Danitumumab adjunctive therapy. No place in either first- or second-line treatment of metastatic colorectal cancer.
    Prescrire Int; 2013 May; 22(138):120. PubMed ID: 23819169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?
    Messersmith WA; Hidalgo M
    Clin Cancer Res; 2007 Aug; 13(16):4664-6. PubMed ID: 17699842
    [No Abstract]   [Full Text] [Related]  

  • 10. Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.
    Wu M; Rivkin A; Pham T
    Clin Ther; 2008 Jan; 30(1):14-30. PubMed ID: 18343240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panitumumab for the treatment of metastatic colorectal cancer: a review.
    Del Prete M; Giampieri R; Faloppi L; Bianconi M; Bittoni A; Andrikou K; Cascinu S
    Immunotherapy; 2015; 7(7):721-38. PubMed ID: 26250414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.
    Cohenuram M; Saif MW
    Anticancer Drugs; 2007 Jan; 18(1):7-15. PubMed ID: 17159497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panitumumab: new drug. Metastatic colorectal cancer: don't make things worse!
    Prescrire Int; 2009 Aug; 18(102):157. PubMed ID: 19743571
    [No Abstract]   [Full Text] [Related]  

  • 14. Panitumumab: a summary of clinical development in colorectal cancer and future directions.
    Argiles G; Dienstmann R; Elez E; Tabernero J
    Future Oncol; 2012 Apr; 8(4):373-89. PubMed ID: 22515440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
    Morse MA
    IDrugs; 2005 Dec; 8(12):974-7. PubMed ID: 16320126
    [No Abstract]   [Full Text] [Related]  

  • 16. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy.
    Serrano C; Markman B; Tabernero J
    Cancer J; 2010; 16(3):226-34. PubMed ID: 20526101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
    Van Cutsem E; Peeters M; Siena S; Humblet Y; Hendlisz A; Neyns B; Canon JL; Van Laethem JL; Maurel J; Richardson G; Wolf M; Amado RG
    J Clin Oncol; 2007 May; 25(13):1658-64. PubMed ID: 17470858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Our experience with panitumumab used for patients with metastatic colorectal cancer].
    Ishii K; Kanou S; Takei R; Haba Y; Ohbatake Y; Noto M; Takeda T; Tani T; Yagi M
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):67-9. PubMed ID: 23306920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panitumumab in colorectal cancer.
    Wainberg ZA; Hecht JR
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):967-73. PubMed ID: 17627455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.